IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Am J Gastroenterol. 2020 Oct;115(10):1719-1721. doi: 10.14309/ajg.0000000000000829.
The risk of coronavirus disease-19 infection for healthcare professionals and patients in hospitals remains unclear.
We investigated whether precautions adopted in our inflammatory bowel disease (IBD) unit have minimized the risks of infection for all patients accessing our facilities in a 1-month period by assessing the rate of coronavirus disease-19 infection in the follow-up period.
Three hundred-twenty patients with IBD were included. None were infected from severe acute respiratory syndrome-coronavirus 2 in the follow-up period. None of the IBD team members were infected.
Neither pharmacological immunosuppression nor access to the hospital seem to be risk factors for infection in patients with IBD.
医院内医护人员和患者感染冠状病毒病-19 的风险仍不清楚。
我们通过评估随访期间冠状病毒病-19 的感染率，调查我们炎症性肠病 (IBD) 病房采取的预防措施是否在 1 个月内将所有使用我们设施的患者的感染风险降到了最低。
纳入了 320 名 IBD 患者。随访期间均未发生严重急性呼吸综合征-冠状病毒 2 感染。IBD 团队成员均未感染。
药物免疫抑制治疗和住院均不是 IBD 患者感染的危险因素。
